tag early-diagnosis 
Pharmaceutical Technology
MAY 19, 2023
While MS is not a terminal diagnosis, the effect of the disease on the CNS can significantly impact patients’ independence and disturb their daily lives. DMTs for MS have a high price tag, particularly in the US. However, they cannot provide a cure and have a very limited impact on halting disease progression.
XTalks
APRIL 18, 2024
Roche has received Breakthrough Device designation from the US Food and Drug Administration (FDA) for its Elecsys pTau217 early Alzheimer’s blood test. However, Roche has several CSF tests on the market, which include assays in the company’s Elecsys line that are used in conjunction with PET in the diagnosis and monitoring of the disease.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
World of DTC Marketing
JUNE 23, 2021
SKIMMERS SUMMARY: Jefferies analysts found doctors have shown strong interest in prescribing Aduhelm for about 35% of early-stage Alzheimer’s patients with mild cognitive impairment after surveying 50 U.S. Not to mention the $56,000 annual price tag. neurologists or psychiatrists currently treating about 12,000 Alzheimer’s patients.
XTalks
OCTOBER 12, 2022
However, the role of MRI in new drug clinical trials can involve diagnosis of lesions and determination of their severity, early identification of therapeutic responders to drug treatment and treatment monitoring and follow-up. For most of this time, MRI mainly was used for qualitative interpretation and simple structural measurements.
XTalks
JUNE 8, 2021
With a price tag of over $2.5 The study also found that early treatment was better. One of the main reasons why Zolgensma has such a hefty price tag is because it has a small market size in the drug manufacturing industry and hence limited potential to save lives on a large scale. Early diagnosis and treatment is vital.”.
Intouch Solutions
APRIL 11, 2024
Pharmacovigilance : Early identification of adverse drug reactions, higher data integrity and faster response times. Offering the physician support from a virtual assistant during the differential diagnosis process where they have access to a more extensive knowledge and experience base.
XTalks
AUGUST 23, 2021
Early symptomatic patients are the ones most likely to drop out of ongoing trials as they’re the target population for aducanumab. After all, wouldn’t early treatment with an anti-amyloid therapy be better than a delayed approach? “I I truly believe it should not be disclosed,” said Dr. Knopman.
Expert insights. Personalized for you.
246 
Let's personalize your content